A research agenda for curing chronic hepatitis B virus infection

Harvey Alter; Timothy Block; Nathaniel Brown; Alan Brownstein; Carol Brosgart; Kyong Mi Chang; Pei Jer Chen; Francis V. Chisari; Chari Cohen; Hashem El-Serag; Jordan Feld; Robert Gish; Jeffrey Glenn; Tim Greten; Haitao Guo; Ju Tao Guo; Yujin Hoshida; Jianming Hu; Kris V. Kowdley; Wenhui Li; Jake Liang; Stephan Locarnini; Anna S. Lok; William Mason; Brian McMahon; Anand Mehta; Robert Perrillo; Peter Revill; Charles M. Rice; Jo Ann Rinaudo; Raymond Schinazi; Christoph Seeger; Kirty Shetty; John Tavis; Fabien Zoulim

doi:10.1002/hep.29509

A research agenda for curing chronic hepatitis B virus infection

Harvey Alter, Timothy Block, Nathaniel Brown, Alan Brownstein, Carol Brosgart, Kyong Mi Chang, Pei Jer Chen, Francis V. Chisari, Chari Cohen, Hashem El-Serag, Jordan Feld, Robert Gish, Jeffrey Glenn, Tim Greten, Haitao Guo, Ju Tao Guo, Yujin Hoshida, Jianming Hu, Kris V. Kowdley, Wenhui LiJake Liang, Stephan Locarnini, Anna S. Lok, William Mason, Brian McMahon, Anand Mehta, Robert Perrillo, Peter Revill, Charles M. Rice, Jo Ann Rinaudo, Raymond Schinazi, Christoph Seeger, Kirty Shetty, John Tavis, Fabien Zoulim

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Original language	English (US)
Pages (from-to)	1127-1131
Number of pages	5
Journal	Hepatology
Volume	67
Issue number	3
DOIs	https://doi.org/10.1002/hep.29509
State	Published - Mar 2018
Externally published	Yes

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.29509

Cite this

Alter, H., Block, T., Brown, N., Brownstein, A., Brosgart, C., Chang, K. M., Chen, P. J., Chisari, F. V., Cohen, C., El-Serag, H., Feld, J., Gish, R., Glenn, J., Greten, T., Guo, H., Guo, J. T., Hoshida, Y., Hu, J., Kowdley, K. V., ... Zoulim, F. (2018). A research agenda for curing chronic hepatitis B virus infection. Hepatology, 67(3), 1127-1131. https://doi.org/10.1002/hep.29509

Alter, H, Block, T, Brown, N, Brownstein, A, Brosgart, C, Chang, KM, Chen, PJ, Chisari, FV, Cohen, C, El-Serag, H, Feld, J, Gish, R, Glenn, J, Greten, T, Guo, H, Guo, JT, Hoshida, Y, Hu, J, Kowdley, KV, Li, W, Liang, J, Locarnini, S, Lok, AS, Mason, W, McMahon, B, Mehta, A, Perrillo, R, Revill, P, Rice, CM, Rinaudo, JA, Schinazi, R, Seeger, C, Shetty, K, Tavis, J & Zoulim, F 2018, 'A research agenda for curing chronic hepatitis B virus infection', Hepatology, vol. 67, no. 3, pp. 1127-1131. https://doi.org/10.1002/hep.29509

@article{c65a2cd93537436996cdf8e87c67f1d4,

title = "A research agenda for curing chronic hepatitis B virus infection",

author = "Harvey Alter and Timothy Block and Nathaniel Brown and Alan Brownstein and Carol Brosgart and Chang, {Kyong Mi} and Chen, {Pei Jer} and Chisari, {Francis V.} and Chari Cohen and Hashem El-Serag and Jordan Feld and Robert Gish and Jeffrey Glenn and Tim Greten and Haitao Guo and Guo, {Ju Tao} and Yujin Hoshida and Jianming Hu and Kowdley, {Kris V.} and Wenhui Li and Jake Liang and Stephan Locarnini and Lok, {Anna S.} and William Mason and Brian McMahon and Anand Mehta and Robert Perrillo and Peter Revill and Rice, {Charles M.} and Rinaudo, {Jo Ann} and Raymond Schinazi and Christoph Seeger and Kirty Shetty and John Tavis and Fabien Zoulim",

note = "Funding Information: Copyright VC 2018 The Authors. Hepatology published by Wiley Periodicals, Inc. on behalf of American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.29509 Potential conflict of interest: Dr. Block owns stock, holds intellectual property rights, and received grants from Arbutus. He is employed by and owns stock in Contravir. He is director and has equity in Glycotest. Dr. Chisari consults for Gilead. Dr. H. Guo owns stock and received grants from Arbutus. He consults for Assembly. He received grants from Alios. Dr. J. Guo received grants from Arbutus. Dr. Lok received grants from Bristol-Myers Squibb and Gilead. Dr. Kowdley consults, advises, and is on the speakers{\textquoteright} bureau for Gilead. Dr. Glenn consults, is employed by, and owns stock in Riboscience. He is employed by and owns stock in Eiger. Dr. Feld consults and received grants from AbbVie, Gilead, Janssen, and Merck. He consults for Contravir. He received grants from Abbott. Dr. Hu consults and received grants from Gilead and Roche. He consults for Sanofi and Arbutus. Dr. El-Serag received grants from Wako, Gilead, and Merck. Dr. Mason consults for Gilead. Dr. Revill received grants from Gilead. Dr. Chang advises Arbutus and Alnylam. Dr. Locarnini consults and received grants from Gilead and Arrowhead. He consults for Roche and Janssen. He received grants from Spring Bank. Dr. Zoulim consults and received grants from Gilead, Janssen, and Roche. He consults for Assembly, Arbutus, Contravir, and Transgene. Dr. Mehta owns stock and holds intellectual property rights in Glycotest. He consults for Insta-Diagnostics. He owns stock in N-Zyme. Dr. Brosgart consults for Dynavax. She is employed by and owns stock in Galmed and Contravir. She was employed by and owns stock in Allergan (formerly Tobira). Dr. Gish consults, advises, is on the speakers{\textquoteright} bureau, and received grants from Gilead. He consults, advises, and is on the speakers{\textquoteright} bureau for AbbVie and Merck. He consults, advises, and owns stock in Arrowhead. He consults, is on the speakers{\textquoteright} bureau, and owns stock in Alexion. He consults and advises AstraZeneca, Contravir, Eiger, Enyo, Genentech, Humabs, Intellia, Intercept, Ionis, Janssen, MedImmune, Nanogen, and Theranos. He consults and is on the speakers{\textquoteright} bureau for Bayer. He consults and owns stock in CoCrystal. He consults for Abbott, AccessBiologics, Novira, Springbank, Transgene, and VitalTherapies. He advises Quest, Biocollections, and Prometheus. He is on the speakers{\textquoteright} bureau for Salix/Valeant. He owns stock in Kinex and RiboSciences. Funding Information: The Hepatitis B Foundation (HBF), a non profit organization, initiated the conversation that led to tbis article by asking the authors about their research priorities. The authors thank HBF staff members Theresa Weizman, Ph.D. and Judith Marchand for invaluable help in manuscript preparation.",

year = "2018",

month = mar,

doi = "10.1002/hep.29509",

language = "English (US)",

volume = "67",

pages = "1127--1131",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - A research agenda for curing chronic hepatitis B virus infection

AU - Alter, Harvey

AU - Block, Timothy

AU - Brown, Nathaniel

AU - Brownstein, Alan

AU - Brosgart, Carol

AU - Chang, Kyong Mi

AU - Chen, Pei Jer

AU - Chisari, Francis V.

AU - Cohen, Chari

AU - El-Serag, Hashem

AU - Feld, Jordan

AU - Gish, Robert

AU - Glenn, Jeffrey

AU - Greten, Tim

AU - Guo, Haitao

AU - Guo, Ju Tao

AU - Hoshida, Yujin

AU - Hu, Jianming

AU - Kowdley, Kris V.

AU - Li, Wenhui

AU - Liang, Jake

AU - Locarnini, Stephan

AU - Lok, Anna S.

AU - Mason, William

AU - McMahon, Brian

AU - Mehta, Anand

AU - Perrillo, Robert

AU - Revill, Peter

AU - Rice, Charles M.

AU - Rinaudo, Jo Ann

AU - Schinazi, Raymond

AU - Seeger, Christoph

AU - Shetty, Kirty

AU - Tavis, John

AU - Zoulim, Fabien

N1 - Funding Information: Copyright VC 2018 The Authors. Hepatology published by Wiley Periodicals, Inc. on behalf of American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.29509 Potential conflict of interest: Dr. Block owns stock, holds intellectual property rights, and received grants from Arbutus. He is employed by and owns stock in Contravir. He is director and has equity in Glycotest. Dr. Chisari consults for Gilead. Dr. H. Guo owns stock and received grants from Arbutus. He consults for Assembly. He received grants from Alios. Dr. J. Guo received grants from Arbutus. Dr. Lok received grants from Bristol-Myers Squibb and Gilead. Dr. Kowdley consults, advises, and is on the speakers’ bureau for Gilead. Dr. Glenn consults, is employed by, and owns stock in Riboscience. He is employed by and owns stock in Eiger. Dr. Feld consults and received grants from AbbVie, Gilead, Janssen, and Merck. He consults for Contravir. He received grants from Abbott. Dr. Hu consults and received grants from Gilead and Roche. He consults for Sanofi and Arbutus. Dr. El-Serag received grants from Wako, Gilead, and Merck. Dr. Mason consults for Gilead. Dr. Revill received grants from Gilead. Dr. Chang advises Arbutus and Alnylam. Dr. Locarnini consults and received grants from Gilead and Arrowhead. He consults for Roche and Janssen. He received grants from Spring Bank. Dr. Zoulim consults and received grants from Gilead, Janssen, and Roche. He consults for Assembly, Arbutus, Contravir, and Transgene. Dr. Mehta owns stock and holds intellectual property rights in Glycotest. He consults for Insta-Diagnostics. He owns stock in N-Zyme. Dr. Brosgart consults for Dynavax. She is employed by and owns stock in Galmed and Contravir. She was employed by and owns stock in Allergan (formerly Tobira). Dr. Gish consults, advises, is on the speakers’ bureau, and received grants from Gilead. He consults, advises, and is on the speakers’ bureau for AbbVie and Merck. He consults, advises, and owns stock in Arrowhead. He consults, is on the speakers’ bureau, and owns stock in Alexion. He consults and advises AstraZeneca, Contravir, Eiger, Enyo, Genentech, Humabs, Intellia, Intercept, Ionis, Janssen, MedImmune, Nanogen, and Theranos. He consults and is on the speakers’ bureau for Bayer. He consults and owns stock in CoCrystal. He consults for Abbott, AccessBiologics, Novira, Springbank, Transgene, and VitalTherapies. He advises Quest, Biocollections, and Prometheus. He is on the speakers’ bureau for Salix/Valeant. He owns stock in Kinex and RiboSciences. Funding Information: The Hepatitis B Foundation (HBF), a non profit organization, initiated the conversation that led to tbis article by asking the authors about their research priorities. The authors thank HBF staff members Theresa Weizman, Ph.D. and Judith Marchand for invaluable help in manuscript preparation.

PY - 2018/3

Y1 - 2018/3

UR - http://www.scopus.com/inward/record.url?scp=85040970152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040970152&partnerID=8YFLogxK

U2 - 10.1002/hep.29509

DO - 10.1002/hep.29509

M3 - Article

C2 - 28877549

AN - SCOPUS:85040970152

SN - 0270-9139

VL - 67

SP - 1127

EP - 1131

JO - Hepatology

JF - Hepatology

IS - 3

ER -

A research agenda for curing chronic hepatitis B virus infection

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this